Cafepharma Today

May 20 2025 - FDA outlines stricter Covid vaccine booster approval standards for healthy people
FDA outlines stricter Covid vaccine booster approval standards for healthy people
AHA warns tariffs could worsen drug shortages, pushes for long-term reform
Surveyed via text, HCPs say they want more interactions with pharma
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA
Fierce Biotech
Tuesday, August 27, 2013 - 11:01am
tags:
Catalyst Pharmaceutical Partners, Firdapse, Biomarin, FDA, breakthrough therapies, Lambert-Eaton myasthenic syndrome
LDR files for $69M IPO following FDA approval of its spinal disc implant
Fierce Medical Devices
Tuesday, August 27, 2013 - 10:58am
tags:
LDR, IPOs, spinal disc implants, devices
Orexigen Readies New Drug Application
Seeking Alpha
Tuesday, August 27, 2013 - 10:56am
tags:
Orexigen, Contrave, obesity, Arena Pharmaceuticals, Belviq, Qsymia, Vivus
Eli Lilly Might Have A Blockbuster Cancer Drug
Seeking Alpha
Tuesday, August 27, 2013 - 10:54am
tags:
Eli Lilly, non-small cell lung cancer, necitumumab
J&J puts Chinese businesses under one chairman there
Yahoo/Reuters
Tuesday, August 27, 2013 - 10:52am
tags:
China, JNJ
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug
Xconomy
Tuesday, August 27, 2013 - 9:57am
tags:
Syndax Pharma, entinostat, cancer
Biomet units lose $2.7M royalty dispute with spine surgeon
Mass Device
Tuesday, August 27, 2013 - 9:51am
tags:
devices, Biomet, royalty disputes
Chelsea Therapeutics Minor NDA Deficiencies Create Opportunity For Huge Gains
Seeking Alpha
Tuesday, August 27, 2013 - 9:34am
tags:
Chelsea Therapeutics, Northera, Parkinson's Disease
Bayer's Nexavar gets priority review as thyroid cancer drug
Reuters
Tuesday, August 27, 2013 - 9:31am
tags:
Bayer, Nexavar, thyroid cancer
California Assembly Passes Bill on Biosimilar Drug Use
Bloomberg
Tuesday, August 27, 2013 - 9:25am
tags:
California, biosimilars
Vasella considers his Novartis results worth $78M payout; canceled noncompete deal was replaced with $5.2M exit package
Fierce Pharma
Tuesday, August 27, 2013 - 9:12am
tags:
Novartis, executive pay, Daniel Vasella
AstraZeneca - Small Deal With Amplimmune Provides No Quick Fixes
Seeking Alpha
Tuesday, August 27, 2013 - 9:09am
tags:
AstraZeneca, Amplimmune, M&A
Amarin Heading In The Right Direction Based On Script Data Trends
Seeking Alpha
Monday, August 26, 2013 - 6:38pm
tags:
Amarin, prescription data, Vascepa
Acura's abuse-deterrent pain drug fails mid-stage study goal
Reuters
Monday, August 26, 2013 - 6:37pm
tags:
abuse-resistant painkillers, Acura Pharmaceuticals, Aversion H&A
Pipeline Setback for Glaxo
Yahoo/Zacks
Monday, August 26, 2013 - 6:35pm
tags:
GSK, Vercirnon, Chron's Disease
Ampio Momentum Continues After Positive Initial Phase III Data
Seeking Alpha
Monday, August 26, 2013 - 6:35pm
tags:
Ampio Pharmaceuticals, Ampion
Will Amgen Stock Continue to Rise After Recent Acquisition?
Wall St. Cheat Sheet
Monday, August 26, 2013 - 6:34pm
tags:
Amgen, M&A, ONYX Pharmaceuticals
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Monday, August 26, 2013 - 1:28pm
tags:
FDA, breakthrough therapies, AbbVie, Alexion, Ariad Pharmaceuticals, Biomarin, Bristol-Myers Squibb, SynaGeva BioPharma, GSK, JNJ, Merck, Novartis, Pharmacyclics, Pfizer, Vertex Pharmaceuticals, daratumumab, ibrutinib, Kalydeco, lambrolizumab, palbociclib, LDK378, SD-101, obinutuzumab, serelaxin, asfotase alfa, bimagrumab, drisapersen, sebelipase alfa
For once, buyer sees bigger gains than seller in Amgen-Onyx deal
Marketwatch
Monday, August 26, 2013 - 12:02pm
tags:
ONYX Pharmaceuticals, M&A, Amgen
Entia Biosciences Completes Parkinson’s Disease Study
Yahoo/Accesswire
Monday, August 26, 2013 - 12:02pm
tags:
Entia Biosciences, Parkinson's Disease, ErgoD2

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.